Skip to main
DNTH
DNTH logo

DNTH Stock Forecast & Price Target

DNTH Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dianthus Therapeutics Inc demonstrates a promising prospective valuation, with recent updates reflecting a $2 increase in their target price, now set at $44. This upward adjustment underscores the market's recognition of the company's innovative pipeline, particularly the development of DNTH103, a novel subcutaneous active C1s antibody targeting severe autoimmune and inflammatory diseases. Additionally, the experienced leadership team further enhances confidence in the company’s ability to navigate the competitive biotech landscape successfully.

Bears say

Dianthus Therapeutics Inc. may face significant challenges in advancing its pipeline due to potential difficulties in raising adequate funds. The reliance on external funding indicates a vulnerability that could stall the development of its key assets, including the subcutaneous active C1s antibody, DNTH103. This financial uncertainty poses a risk to the company's long-term viability and growth prospects in the competitive biotechnology sector.

DNTH has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Magenta Therapeutics Inc (DNTH) Forecast

Analysts have given DNTH a Strong Buy based on their latest research and market trends.

According to 9 analysts, DNTH has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Magenta Therapeutics Inc (DNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.